FDMT
NASDAQ · Biotechnology
4D Molecular Therapeutics In
$12.25
+1.00 (+8.89%)
Open$11.46
Previous Close$11.25
Day High$12.57
Day Low$11.28
52W High$16.93
52W Low$6.96
Volume—
Avg Volume977.6K
Market Cap676.74M
P/E Ratio—
EPS$-2.76
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+72.3% upside
Current
$12.25
$12.25
Target
$21.11
$21.11
$12.84
$21.11 avg
$26.25
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 83.30M | 286.9K | 228.58M |
| Net Income | -136,967,969 | -1,099,890,361 | -57,732,834 |
| Profit Margin | -164.4% | -413,039.5% | -25.3% |
| EBITDA | -151,380,583 | -1,322,641,633 | -107,016,126 |
| Free Cash Flow | — | — | -89,291,698 |
| Rev Growth | +200.8% | -87.3% | +10.3% |
| Debt/Equity | — | — | 0.12 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.16 | +0.29% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $463.66 | -0.34% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $169.91 | +0.35% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $550.07 | -0.15% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $911.56 | -0.91% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $151.28 | -3.40% | 7.7 | 20.98B |